BofA Securities: Raises HANSOH PHARMA (03692) target price to HK$29, reiterates "Buy" rating.

28/04/2025

Hans Pharmaceuticals (03692) reported a 76.9% increase in sales of Almonertinib tablets in the first two months of this year, driving strong sales performance for the company.

Bank of America Securities released a research report stating that HANSOH PHARMA (03692) saw a 76.9% increase in sales of its almonertinib tablets in the first two months of this year, driving strong sales performance for the company. As a result, revenue forecasts for 2025, 2026, and 2027 were raised by 1.9%, 2.5%, and 2.7% respectively, with the target price increased from HK$24.8 to HK$29. Due to its strong research and development capabilities and expanding indications for its existing main products, the "buy" rating was reiterated.

Berkshire Hathaway (BRK.A.US) cash reserves slightly decreased, Q2 net profit halved, Kraft Heinz Company became a "minefield"

Huajin Securities: A-shares may have started a comprehensive slow bull trend. In the short term, it is recommended to continue to allocate technology-related CKH HOLDINGS cyclicals on dips.

CITIC SEC: AI is the biggest DRIVER of the semiconductor industry, looking at domestic alternatives in the cloud and downstream increment in terminals.

Berkshire Hathaway (BRK.A.US) cash reserves slightly decreased, Q2 net profit halved, Kraft Heinz Company became a "minefield"

Huajin Securities: A-shares may have started a comprehensive slow bull trend. In the short term, it is recommended to continue to allocate technology-related CKH HOLDINGS cyclicals on dips.

CITIC SEC: AI is the biggest DRIVER of the semiconductor industry, looking at domestic alternatives in the cloud and downstream increment in terminals.